VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE)
CURE.DE is a passive ETF by VanEck tracking the investment results of the MVIS Global Future Healthcare ESG. CURE.DE launched on Sep 2, 2022 and has a 0.35% expense ratio.
ETF Info
| ISIN | IE000B9PQW54 |
|---|---|
| WKN | A3DSGJ |
| Issuer | VanEck |
| Inception Date | Sep 2, 2022 |
| Category | Health & Biotech Equities |
| Index Tracked | MVIS Global Future Healthcare ESG |
| Domicile | Ireland |
| Distribution Policy | Accumulating |
| Asset Class | Equity |
Expense Ratio
CURE.DE has a high expense ratio of 0.35%, indicating higher-than-average management fees.
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of €10,000 in VanEck Genomics and Healthcare Innovators UCITS ETF A, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
VanEck Genomics and Healthcare Innovators UCITS ETF A had a return of -5.77% year-to-date (YTD) and -8.77% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -5.77% | 5.21% |
| 1 month | -6.82% | -4.30% |
| 6 months | 9.12% | 18.42% |
| 1 year | -8.77% | 21.82% |
| 5 years (annualized) | N/A | 11.27% |
| 10 years (annualized) | N/A | 10.33% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -1.15% | 0.64% | 1.65% | |||||||||
| 2023 | -11.76% | 5.84% | 11.54% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CURE.DE is 4, indicating that it is in the bottom 4% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
VanEck Genomics and Healthcare Innovators UCITS ETF A(CURE.DE)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the VanEck Genomics and Healthcare Innovators UCITS ETF A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the VanEck Genomics and Healthcare Innovators UCITS ETF A was 29.12%, occurring on Nov 10, 2023. The portfolio has not yet recovered.
The current VanEck Genomics and Healthcare Innovators UCITS ETF A drawdown is 20.55%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -29.12% | Sep 12, 2022 | 301 | Nov 10, 2023 | — | — | — |
| -1.58% | Sep 6, 2022 | 1 | Sep 6, 2022 | 1 | Sep 7, 2022 | 2 |
Volatility
Volatility Chart
The current VanEck Genomics and Healthcare Innovators UCITS ETF A volatility is 5.60%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.